SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats-Reference-Cited by-同舟云学术

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Published:2014-03 Issue: Volume:727 Page:66-74
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Yokono Masanori^ORCID,Takasu Toshiyuki,Hayashizaki Yuka,Mitsuoka Keisuke,Kihara Rumi,Muramatsu Yuko,Miyoshi Sousuke,Tahara Atsuo,Kurosaki Eiji,Li Qun,Tomiyama Hiroshi,Sasamata Masao,Shibasaki Masayuki,Uchiyama Yasuo

Publisher

Elsevier BV

Subject

Pharmacology

Reference39 articles.

1. Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats;Alemzadeh;Metabolism,2008

2. Diazoxide attenuates insulin secretion and hepatic lipogenesis in Zucker diabetic fatty rats;Alemzadeh;Med. Sci. Monit.,2005

3. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin;Bolinder;J. Clin. Endocrinol. Metab.,2012

4. Diabesity: therapeutic options;Colagiuri;Diabetes Obes. Metab.,2010

5. The role of the sympathetic nervous system in obesity-related hypertension;da Silva;Curr. Hypertens. Rep.,2009

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits;Cellular Signalling;2024-10

2. Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study;BMC Endocrine Disorders;2024-08-19

3. The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review;Journal of Mind and Medical Sciences;2024-04-30

4. SGLT‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors;Clinical Pharmacology & Therapeutics;2024-02-09

5. Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2024-01